Description

Endometriosis is a disease that affects between 6 and 10% of women of childbearing age. It is defined by the presence of endometrial tissue outside the uterine cavity, most often in the ovaries or the peritoneal cavity. Endometriomas are ovarian cysts whose lining is composed of ectopic endometrium and which contain a liquid resulting from the accumulation of menstrual debris. Between 17% and 44% of women with endometriosis have one or more ovarian endometriomas (i.e. between 1% and 5% of women). The clinical symptoms of endometriomas include pelvic pain (dysmenorrhoea, chronic pelvic pain or dyspareunia) and/or infertility. The standard treatment for endometriomas is laparoscopic intraperitoneal cystectomy. This treatment has been shown to be associated with a lower rate of recurrence of painful symptoms than simple cyst drainage, and with higher pregnancy rates. Nevertheless, cystectomy can lead to a reduction in ovarian reserve due to the removal of adjacent healthy ovarian tissue, particularly when there is no cleavage plane between the ovary and the endometrioma. Excessive coagulation to ensure haemostasis after cystectomy could also contribute to this reduction in ovarian reserve. Other methods have been developed to manage endometriomas while preserving the ovarian reserve: therapeutic abstention, drainage, laser or plasma energy ablation and sclerotherapy. Endometrioma sclerotherapy is one of the most promising techniques for reducing the risk of recurrence while preserving the ovarian reserve. This technique involves injecting a sclerosing agent into the cystic cavity, which has been drained beforehand, in order to create an abrasion of the cystic epithelium, resulting in inflammation and fibrosis that can lead to the permanent destruction of the cyst. This very simple technique is effective and low-risk for treating endometriomas:

• Recurrence rate between 0 and 62.5% depending on the protocol (recurrence rate after cystectomy between 6 and 67%).
• Improvement in pain in 68 to 96% of patients.
• Improvement in ovarian reserve compared with intraperitoneal cystectomy (increase in antral follicle count and AMH and higher number of oocytes harvested during subsequent in vitro fertilisation).
• Low complication rate: transient abdominal pain (1.8 - 15.3%), transient alcohol intoxication (3.8%).

Most of what is known about serotherapy comes from non-comparative prospective studies and a few randomised trials comparing sclerotherapy with either no treatment or simple drainage of the endometrioma. In addition, most studies have been conducted in the specific context of endometriomas recurring after cystectomy. To date, there is no comparative trial between sclerotherapy and intraperitoneal cystectomy (reference treatment).

We aim to conduct a single-centre randomised controlled non-inferiority trial comparing sclerotherapy and intraperitoneal cystectomy for the treatment of endometriomas.

The main hypothesis of the study is that sclerotherapy is not inferior to cystectomy in terms of reducing painful symptoms one year after the operation and that it is superior to cystectomy on one or more of the following criteria: preservation of ovarian reserve, operative complications, post-operative pain, patient acceptability/satisfaction.

The main objective is to investigate the non-inferiority of sclerotherapy of endometriomas one year after the operation in terms of reduction of painful symptoms compared with laparoscopic cystectomy. The reduction in painful symptoms was defined by the difference in the number of millimetres of VAS for pain between the preoperative consultation and the consultation one year after the operation, according to the answer to the question : " Indicate the subjective level of your endometriosis-related pain over the last 4 weeks by simply drawing a line through the line".

The secondary objectives were to compare the two techniques:

• The evolution of the 3 components of endometriosis-related pain (chronic pelvic pain, dysmenorrhoea and dyspareunia) with a VAS evaluation at 3 months and one year.
• Subjective evaluation of the evolution of treatment-related symptoms at 3 months and one year (based on self-assessment using the Clinical Global Impression Scale (CGI-S)).
• Patient satisfaction at 3 months (based on the SSQ-8 questionnaire).
• The endometrioma recurrence rate at one year (defined as the visualisation of an endometrioma with a maximum diameter greater than 3 cm on the same ovary on ultrasound or pelvic MRI one year after the operation).
• Pregnancy rate at one year for all patients (defined by at least one analysis of a quantitative plasma HCG level greater than 100 IU/ml in the year following the operation).
• The one-year pregnancy rate for patients who have expressed a desire to become pregnant within the year (defined by at least one analysis of the quantitative plasma HCG level greater than 100 IU/ml within the year following the procedure). Assessment of ovarian reserve at one year (defined by the AMH value one year after the operation and by the antral follicle count between the 2nd and 5th day of the cycle one year after the operation).
• Changes in quality of life at 3 months and one year (based on responses to the SF-36 questionnaire).
• The rate of per- and post-operative complications.
• Duration of the operation and length of post-operative hospitalisation.

The number of patients to be included will be 64, calculated to demonstrate non-inferiority between sclerotherapy and cystectomy for the primary endpoint.